MCID: GLL018
MIFTS: 56

Gallbladder Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 52 36 54 42 15
Gallbladder Carcinoma 12 54 15 17 71
Malignant Neoplasm of Gallbladder 12 71 32
Gallbladder Neoplasm 12 17 71
Carcinoma of Gallbladder 12 6
Malignant Neoplasm of Gallbladder Localized 71
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 43
Gallbladder Ca 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3121 DOID:4948
KEGG 36 H00047
ICD9CM 34 156.0
MeSH 43 D005706
SNOMED-CT 67 93810008
ICD10 32 C23
UMLS 71 C0016978 C0153452 C0235782 more

Summaries for Gallbladder Cancer

MedlinePlus : 42 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to cholangiocarcinoma and gallbladder adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gallbladder Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are MAPK Pathway and DNA Damage Response (only ATM dependent). The drugs Sevoflurane and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include gallbladder, liver and lymph node.

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

KEGG : 36 Gallbladder cancer (GBC) is a relatively uncommon neoplasm, however its prognosis is poor with less than a 5% 5-year survival rate. There are considerable geographic differences in its incidence and etiology. Two main pathways of GBC pathogenesis have been identified. The most common is associated with gallstones and chronic inflammation of the gallbladder, whereas a second, less frequent pathway is associated with a congenital abnormality of the pancreatic bile-duct junction, which is particularly common in Japan. TP53 inactivation has an important and early role in GBC associated with gallstones and chronic inflammation. Although KRAS mutations are rarely detected in GBC associated with gallstones, they are frequent and early events in tumors associated with congenital abnormality of the pancreatic bile-duct junction.

Wikipedia : 74 Gallbladder cancer is a relatively uncommon cancer, with an incidence of fewer than 2 cases per 100,000... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.8 UCA1 TUG1 TP53 PIK3CA MALAT1 H19
2 gallbladder adenocarcinoma 31.9 TP53 PIK3CA ERBB2
3 gallbladder disease 31.8 TP53 GCASPC ERBB2 CYTOR
4 adenocarcinoma 31.7 TP53 PIK3CA MALAT1 H19 ERBB2
5 intrahepatic cholangiocarcinoma 31.5 TUG1 TP53 ERBB2 CCAT1
6 bladder cancer 30.8 UCA1 TUG1 TP53 PIK3CA MEG3 MALAT1
7 carcinosarcoma 30.7 TP53 PIK3CA ERBB2
8 embryonal sarcoma 30.6 TP53 MALAT1
9 retinoblastoma 30.6 TP53 MEG3 MALAT1 HOTAIR CCAT1
10 retinitis pigmentosa 11 30.5 UCA1 TP53 HOTAIR
11 kidney cancer 30.4 TP53 PIK3CA MEG3 MALAT1 HOTAIR H19
12 leukemia, chronic myeloid 30.4 UCA1 TP53 MEG3 HOTAIR H19 ERBB2
13 gastric adenocarcinoma 30.4 TP53 PIK3CA HOTAIR H19 ERBB2
14 laryngeal squamous cell carcinoma 30.3 TP53 MALAT1 HOTAIR H19 CDKN2B-AS1 CCAT1
15 small cell cancer of the lung 30.3 TUG1 TP53 PIK3CA MALAT1 HOTAIR
16 hepatoblastoma 30.2 TUG1 TP53 H19 CRNDE
17 myeloma, multiple 30.2 UCA1 TUG1 TP53 MEG3 MALAT1 HOTAIR
18 squamous cell carcinoma 29.9 UCA1 TUG1 TP53 PIK3CA MALAT1 HOTAIR
19 leukemia, acute myeloid 29.8 UCA1 TUG1 TP53 MEG3 MALAT1 HOTAIR
20 melanoma 29.6 UCA1 TP53 PIK3CA MEG3 MALAT1 LINC-ROR
21 lung cancer susceptibility 3 29.6 TUG1 TP53 PIK3CA NPTN-IT1 MEG3 MALAT1
22 pancreatic cancer 29.3 UCA1 TUG1 TP53 PIK3CA MEG3 MALAT1
23 renal cell carcinoma, nonpapillary 29.3 UCA1 TUG1 TP53 PIK3CA NPTN-IT1 MALAT1
24 cervical cancer 29.2 UCA1 TUG1 TP53 PIK3CA NPTN-IT1 MEG3
25 hepatocellular carcinoma 29.1 UCA1 TUG1 TP53 PIK3CA NPTN-IT1 MEG3
26 colorectal cancer 29.1 UCA1 TUG1 TP53 PIK3CA NPTN-IT1 MEG3
27 breast cancer 29.1 UCA1 TUG1 TP53 PIK3CA MEG3 MALAT1
28 ovarian cancer 29.0 UCA1 TUG1 TP53 PIK3CA MEG3 MALAT1
29 lung cancer 29.0 UCA1 TUG1 TP53 PIK3CA MEG3 MALAT1
30 gastric cancer 28.2 UCA1 TUG1 TP53 PIK3CA NPTN-IT1 MEG3
31 adenosquamous gallbladder carcinoma 12.6
32 carcinoma of gallbladder and extrahepatic biliary tract 12.3
33 biliary tract cancer 11.6
34 gallbladder small cell carcinoma 11.5
35 bile duct cancer 11.5
36 gallbladder disease 1 10.9
37 cholecystitis 10.8
38 gastric papillary adenocarcinoma 10.8 TP53 ERBB2
39 marek disease 10.7 TP53 H19
40 apocrine adenosis of breast 10.7 TP53 ERBB2
41 parotid gland cancer 10.7 TP53 ERBB2
42 endometrial adenocarcinoma 10.7 TP53 MALAT1 ERBB2
43 rare head and neck tumor 10.7 TP53 PIK3CA
44 comedo carcinoma 10.7 TP53 ERBB2
45 breast squamous cell carcinoma 10.7 TP53 PIK3CA ERBB2
46 breast sarcoma 10.7 TP53 PIK3CA ERBB2
47 ovarian carcinosarcoma 10.7 TP53 PIK3CA ERBB2
48 pleomorphic adenoma carcinoma 10.7 TP53 ERBB2
49 uterine corpus serous adenocarcinoma 10.7 TP53 PIK3CA ERBB2
50 vulvar disease 10.7 TP53 PIK3CA ERBB2

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Desflurane Approved Phase 4 57041-67-5 42113
3 Platelet Aggregation Inhibitors Phase 4
4 Anesthetics, Inhalation Phase 4
5 Ulipristal acetate Phase 4 126784-99-4
6
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
12
Citalopram Approved Phase 3 59729-33-8 2771
13 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
14 Hormone Antagonists Phase 3
15 Hormones Phase 3
16 Liver Extracts Phase 3
17 Central Nervous System Depressants Phase 3
18 Cola Phase 3
19 Gastrointestinal Agents Phase 3
20 Serotonin Antagonists Phase 3
21
protease inhibitors Phase 3
22 BB 1101 Phase 3
23 Anti-Anxiety Agents Phase 3
24 Antipruritics Phase 3
25 Antipsychotic Agents Phase 3
26 Tranquilizing Agents Phase 3
27 Anti-Inflammatory Agents Phase 3
28 HIV Protease Inhibitors Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 glucocorticoids Phase 3
31 Analgesics Phase 3
32 Anesthetics Phase 3
33 Anesthetics, General Phase 3
34 Narcotics Phase 3
35 Analgesics, Opioid Phase 3
36 Adjuvants, Anesthesia Phase 3
37 Anesthetics, Intravenous Phase 3
38 Anti-Bacterial Agents Phase 3
39 Antibiotics, Antitubercular Phase 3
40 Protective Agents Phase 3
41 Antidotes Phase 3
42 Vitamin B Complex Phase 3
43 Trace Elements Phase 3
44 Vitamins Phase 3
45 Micronutrients Phase 3
46 Nutrients Phase 3
47 Hematinics Phase 3
48 Antiemetics Phase 3
49 Emetics Phase 3
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 211)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
3 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
4 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
5 A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
6 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
7 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
8 Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial Completed NCT00391183 Phase 2, Phase 3
9 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
10 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
11 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
12 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
13 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
14 Dexamethasone Improves Postoperative Symptoms in Patients Undergoing Elective Laparoscopic Cholecystectomy: A Randomised Clinical Trial. Completed NCT01030614 Phase 3 Dexamethasone;placebo
15 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
17 Perioperative Chemotherapy Prior To and After Reoperation for Incidental Gallbladder Cancer - An International, Randomized Phase III Trial Recruiting NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
18 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824(Bintrafusp Alfa) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 M7824;Placebo;Gemcitabine;Cisplatin
19 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
20 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
21 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
22 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
23 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
24 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy Active, not recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
25 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
26 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
27 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
28 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
29 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
30 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
31 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
32 Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer Unknown status NCT03144856 Phase 2 Apatinib
33 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
34 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
35 A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
36 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
37 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
38 A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
39 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
40 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
41 A Phase II Study of Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma, Including Carcinoma of the Gallbladder and Biliary Tract Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
42 A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
43 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
44 A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors Completed NCT00003276 Phase 2 irinotecan hydrochloride
45 Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction Completed NCT00003923 Phase 2 porfimer sodium
46 An Unicentric RCT About Novel Radiation Stent Versus Nitinol SEMS for Palliative Treatment of Malignant Biliary Stricture Completed NCT01320241 Phase 2
47 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
48 A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder Completed NCT00075504 Phase 2 triapine;gemcitabine
49 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
50 A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma Completed NCT00033462 Phase 2 erlotinib hydrochloride

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

19
Gallbladder

MalaCards organs/tissues related to Gallbladder Cancer:

40
Liver, Lymph Node, Breast, Pancreas, Lung, Skin, Endothelial

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 4850)
# Title Authors PMID Year
1
Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer. 61 42
31586263 2019
2
Renal Cell Carcinoma Presenting as a Mass of the Gallbladder. 42
31638537 2019
3
Survival : a rare outcome in large cell neuroendocrine carcinoma of the gallbladder. 42
31566333 2019
4
Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma. 54 61
20037816 2009
5
Expression of nm23, KAI1 and spiral computed tomography findings in primary gallbladder carcinoma. 54 61
19951590 2009
6
Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase. 54 61
18946757 2008
7
Heparanase expression in gallbladder carcinoma and its correlation to prognosis. 54 61
17524042 2008
8
Heparanase and gallbladder cancer: new insights into understanding tumor growth and invasion. 54 61
18318817 2008
9
Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. 54 61
17384652 2007
10
CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. 54 61
17465213 2007
11
Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. 54 61
17287171 2007
12
Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. 54 61
17260103 2007
13
Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. 54 61
18158568 2007
14
Potential role of N-myristoyltransferase in cancer. 54 61
16846646 2007
15
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. 54 61
16820886 2006
16
Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with gallbladder carcinoma. 54 61
16794394 2006
17
Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. 54 61
16039043 2006
18
[Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo]. 54 61
16784656 2006
19
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms]. 54 61
16681930 2006
20
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. 54 61
16619549 2006
21
The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells. 54 61
16309194 2005
22
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. 54 61
15870882 2005
23
Expression of homeodomain protein CDX2 in gallbladder carcinomas. 54 61
15645288 2005
24
Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma. 54 61
15821928 2005
25
Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. 54 61
15832413 2005
26
Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. 54 61
15655836 2005
27
An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. 54 61
15578423 2005
28
[Detection of bone marrow micrometastases in patients with gallbladder cancer]. 54 61
15743160 2004
29
Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells. 54 61
15567755 2004
30
Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. 54 61
15573254 2004
31
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. 54 61
15460847 2004
32
[The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism]. 54 61
15312360 2004
33
Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. 54 61
18333072 2004
34
Potent inhibitor of N-myristoylation: a novel molecular target for cancer. 54 61
14633729 2003
35
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. 54 61
14527906 2003
36
Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. 54 61
12969785 2003
37
Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. 54 61
12692194 2003
38
Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. 54 61
12532418 2003
39
[Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. 54 61
12654182 2003
40
A case of gallbladder carcinoma diagnosed preoperatively by the detection of human telomerase reverse transcriptase mRNA in endoscopically obtained gallbladder bile. 54 61
12561014 2003
41
Mutation analysis of K-ras and beta-catenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. 54 61
12469220 2003
42
Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinoma. 54 61
12680166 2003
43
Expression of MMP-2,TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. 54 61
12439941 2002
44
[Subserous gallbladder carcinoma: expression of cadherine-catenine complex]. 54 61
12611235 2002
45
The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. 54 61
14607700 2002
46
Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review). 54 61
12239600 2002
47
Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. 54 61
11986189 2002
48
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. 54 61
11677947 2001
49
MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. 54 61
11295067 2001
50
Increased expression of N-myristoyltransferase in gallbladder carcinomas. 54 61
10813869 2000

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6 (show all 22) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
2 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
3 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr)SNV Pathogenic/Likely pathogenic 127815 rs587780070 17:7578395-7578395 17:7675077-7675077
4 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
5 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic/Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
6 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
7 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
8 ERBB2 NM_004448.3(ERBB2):c.2524G>A (p.Val842Ile)SNV Pathogenic/Likely pathogenic 375994 rs1057519738 17:37881332-37881332 17:39725079-39725079
9 TP53 NM_000546.5(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic/Likely pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
10 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr)SNV Likely pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
11 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro)SNV Likely pathogenic 376664 rs1057520002 17:7577560-7577560 17:7674242-7674242
12 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala)SNV Likely pathogenic 376665 rs1057520002 17:7577560-7577560 17:7674242-7674242
13 ERBB3 NM_001005915.1(ERBB3):c.310G>A (p.Val104Met)SNV Likely pathogenic 376410 rs1057519893 12:56478854-56478854 12:56085070-56085070
14 ERBB3 NM_001005915.1(ERBB3):c.310G>T (p.Val104Leu)SNV Likely pathogenic 376411 rs1057519893 12:56478854-56478854 12:56085070-56085070
15 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe)SNV Likely pathogenic 12359 rs28934573 17:7577559-7577559 17:7674241-7674241
16 TP53 NM_000546.5(TP53):c.722C>G (p.Ser241Cys)SNV Likely pathogenic 177791 rs28934573 17:7577559-7577559 17:7674241-7674241
17 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp)SNV Likely pathogenic 376610 rs587780070 17:7578395-7578395 17:7675077-7675077
18 TP53 NM_000546.5(TP53):c.536A>C (p.His179Pro)SNV Likely pathogenic 376611 rs1057519991 17:7578394-7578394 17:7675076-7675076
19 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn)SNV Conflicting interpretations of pathogenicity 376609 rs587780070 17:7578395-7578395 17:7675077-7675077
20 TP53 NM_000546.5(TP53):c.523C>T (p.Arg175Cys)SNV Conflicting interpretations of pathogenicity 245851 rs138729528 17:7578407-7578407 17:7675089-7675089
21 TP53 NM_000546.5(TP53):c.536A>T (p.His179Leu)SNV Uncertain significance 376608 rs1057519991 17:7578394-7578394 17:7675076-7675076
22 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg)SNV Uncertain significance 376606 rs1057519991 17:7578394-7578394 17:7675076-7675076

Cosmic variations for Gallbladder Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87804005 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3
2 COSM91859716 biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3
3 COSM134614922 biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3
4 COSM134990112 biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 3

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.64 TP53 PIK3CA ERBB2
2 11.56 TP53 PIK3CA ERBB2
3 11.3 TP53 PIK3CA ERBB2
4 11.17 TP53 PIK3CA ERBB2
5 10.95 TP53 PIK3CA ERBB2
6 10.1 UCA1 TP53 MEG3 LINC-ROR HOTAIR

GO Terms for Gallbladder Cancer

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....